Tandem Diabetes Care, Inc.

As of June 30, 2026, Tandem Diabetes Care, Inc. carries a market capitalization of 1.06B, placing it among publicly traded companies globally. Its enterprise value stands at 1.35B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Tandem Diabetes Care, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, Tandem Diabetes Care, Inc. has 69.54M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.00, and the price-to-book ratio stands at 8.16.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.29 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 1.35B versus a market cap of 1.06B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Tandem Diabetes Care, Inc. maintains a current ratio of 3.18, meaning it holds 3.2x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 566.96, indicating elevated leverage, while an interest coverage ratio of -4.38 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Tandem Diabetes Care, Inc. posted a negative return on equity (ROE) of -48.03, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.24, reflecting losses generated across the asset base. The company generates approximately 410,410.64 in revenue per employee across its workforce of 2,537.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.30 indicates how many times Tandem Diabetes Care, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Tandem Diabetes Care, Inc. recorded 2.32M in income tax expense. The company reported a pretax loss of -61.00M and -63.31M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Tandem Diabetes Care, Inc.'s stock has gained approximately 14.02% over the past 52 weeks. The 50-day moving average sits at 18.55, while the 200-day moving average is 19.14.

Over the twelve months ended June 30, 2026, Tandem Diabetes Care, Inc. generated 1.04B in revenue and converted that into -63.31M in net income, yielding earnings per share of -0.93. EBITDA reached -27.83M, while operating income came in at -45.79M.

As of June 30, 2026, Tandem Diabetes Care, Inc. holds 456.00M in cash and equivalents against 739.25M in total debt, resulting in a net debt position of 539.76M. Total book value stands at 130.39M, with working capital of 551.63M providing operational flexibility.

Tandem Diabetes Care, Inc. produced -5.52M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -56.22M in capital expenditures, free cash flow totaled -61.74M - equivalent to -0.90 per share.

Over the twelve months ended June 30, 2026, Tandem Diabetes Care, Inc. posted a gross margin of 56.01, reflecting its pricing power and cost economics. The operating margin of -4.40 and net profit margin of -6.08 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -5.91: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -26.07, meaning Tandem Diabetes Care, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Tandem Diabetes Care, Inc.'s most recent stock split took place on October 10, 2017 with a 10:1 split ratio.

As of June 30, 2026, Tandem Diabetes Care, Inc. has an Altman Z-Score of 0.40, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.